HFNT vs. COT in COVID-19

NACompletedINTERVENTIONAL
Enrollment

364

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

September 22, 2021

Study Completion Date

October 25, 2021

Conditions
Covid19Acute Respiratory Failure
Interventions
DEVICE

High Flow Nasal Therapy

High flow nasal therapy will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%.

DEVICE

Conventional Oxygen Therapy

Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.

Trial Locations (27)

Unknown

Department of Anesthesiology, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa

Department of Emergency Medicine, Faculty of Medicine, University of Thessaly, Larissa

UO di Pronto Soccorso e Medicina d'Urgenza Humanitas Research Hospital, Rozzano

U.O. di Medicina interna AULSS 7 Pedemontana, Bassano del Grappa

Pulmonology and Respiratory Intensive Care Unit, S. Donato Hospital, Arezzo, Italy, Arezzo

Institute of Respiratory Disease, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari, Bari

Ospedale di Carpi, Carpi

"Respiratory Medicine Unit, Policlinico-Vittorio Emanuele San Marco University Hospital, Catania, Italy", Catania

UO di Medicina d'Urgenza AOU Policlinico Vittorio Emanuele San Marco di Catania, Catania

Respiratory Section, Department of Translational Medicine, University of Ferrara. AOU Ferrara Arcispedale S. Anna. U.O. Pneumologia, Ferrara

Department of Medical and Surgical Sciences, University of Foggia. Institute of Respiratory Diseases, University Hospital 'Policlinico Riuniti', Foggia

UO di Pneumologia ASST Fatebenefratelli Sacco, Milan

AO DEI COLLI - PO Monaldi UO di Pneumologia e Fisiopatologia Respiratoria, Napoli

AOU San Luigi Gonzaga, Orbassano

"Emergency Department, S. Maria della Misericordia Hospital, Perugia, Italy.", Perugia

U.O. di Pneumologia Azienda USL di Pescara, Pescara

"UO di Pronto Soccorso e Medicina d'Urgenza AUSL Romagna PO Rimini Ospedale Inferni", Rimini

U.O. di PneumoCovid Azienda Ospedaliera San Giovanni di Roma, Roma

UO di Pneumologia Ospedale S. Bartolomeo, Sarzana

Department of Pneumology, A.O.U. Città della Salute e della Scienza of Turin, Italy., Turin

U.O. di Pneumologia ASST Settelaghi Ospedale Circolo Fondazione Macchi, Varese

U.O. Medicina Respiratoria del Policlinico G.B. Rossi, Verona

U.O. di Pneumotisiologia Ospedale di Vittorio Veneto Azienda ULSS 2 Marca Trevigiana, Vittorio Veneto

Department of Pneumonology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice

Hospital Prof. Doutor Fernando Fonseca, Pneumologia, Amadora

Hospital Parc Taulí de Sabadell, Pneumologia, Sabadell

Dokuz Eylül University, Izmir

All Listed Sponsors
collaborator

Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele

OTHER

lead

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

OTHER

NCT04655638 - HFNT vs. COT in COVID-19 | Biotech Hunter | Biotech Hunter